Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.